Third Harmonic Bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Third Harmonic Bio Inc in the first quarter 2025?
Third Harmonic Bio Inc achieved a return on average equity (ROE) of 19.27 % in its first quarter 2025 a new company high.

ROE has advanced compared to 16.53% in the fourth quarter 2024, due to net income growth.

Within the Major Pharmaceutical Preparations industry 30 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 614, from total ROE ranking in the fourth quarter 2024 at 752.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Equity Change	3.46 %	5.97 %	8.02 %	-7.66 %	-
Y / Y Net Income Change	101.55 %	91.73 %	87.92 %	41.63 %	-13.53 %
Net Income (TTM) in Millions	53	45	39	33	30
Return On Equity (TTM)	19.27 %	16.53 %	14.46 %	12.33 %	10.93 %
THRD's Total Ranking	# 614	# 752	# 775	# 1014	# 0
Equity (TTM) in Millions	273	285	295	257	264
Seq. Equity Change	-4.39 %	-3.29 %	14.86 %	-2.58 %	-2.08 %
Seq. Net Income Change	20.81 %	-5.01 %	28.88 %	36.29 %	14.92 %

Back to THRD Management Effectiveness >> THRD's 5 Years Annual ROE >> Compare THRD ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 31
Sector	# 75
Overall	# 614

Return On Equity Statistics
High	Average	Low
19.27 %	11.15 %	4.45 %
(Mar 31 2025)		(Sep 30 2023)

THRD Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	285	269	289	0	0
Y / Y Equity Change	5.97 %	-6.91 %	-	-	-
Net Income in Millions	45	31	35	0	0
Y / Y Net Income Change	47.51 %	-12.32 %	-	-	-
Return On Equity	15.95 %	11.46 %	12.16 %	-	-

Back to THRD Management Effectiveness >> THRD's 5 Years Annual ROE >> Compare THRD ROE to its Competitors

Annual Roe Comment

In 2024 ROE improved to 15.95 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
THRD's' Return on Equity at Yahoo Finance
THRD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for THRD's Competitors
Subscribers only: Roe for Third Harmonic Bio Inc 's Suppliers
Subscribers only: Return On Equity for THRD's Customers

Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector	ROE
Agios Pharmaceuticals Inc	50.31 %
Zoetis Inc	50.22 %
Puma Biotechnology Inc	49.30 %
Edwards Lifesciences Corporation	44.69 %
Sbc Medical Group Holdings Incorporated	44.32 %
Tenet Healthcare Corp	42.42 %
Agilent Technologies inc	41.87 %
Waters Corporation	38.48 %
Merck and Co Inc	38.15 %
Hims and Hers Health Inc	35.97 %
Acadia Pharmaceuticals Inc	35.32 %
Insulet Corporation	34.53 %
Lifevantage Corp	32.20 %
Bristol myers Squibb Company	31.93 %
Gilead Sciences Inc	31.85 %
Nutriband Inc	30.78 %
Abbott Laboratories	30.59 %
Concentra Group Holdings Parent Inc	30.50 %
Johnson and Johnson	29.95 %
X4 Pharmaceuticals Inc	29.32 %
Pro dex Inc	29.30 %
Prestige Consumer Healthcare Inc	28.91 %
Biomx Inc	28.29 %
Catalyst Pharmaceuticals Inc	28.28 %
Ge Healthcare Technologies Inc	26.61 %
Whitehawk Therapeutics Inc	26.18 %
Chemed Corporation	26.03 %
Msa Safety Inc	25.67 %
Resmed Inc	25.66 %
Alkermes Plc	25.41 %

Date modified: 2026-09-08T15:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.